TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04374916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Premaquick®
Description: Vaginal secretions are collected prior to any vaginal or endovaginal ultrasound examination to avoid false positives, with the nylon swab provided with the test (placed in the posterior fornix of the vagina for 10 seconds).Then the samples are tested with the Premaquick test. Results are obtained in 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARTOSURE®
Description: An immunochromatographic test wich determines the qualitative in vitro detection of placental alpha microglobulin-1 (PAMG-1) in cervico-vaginal secretions.
Study: NCT01699152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 citrate
Description: TG02 citrate capsules
Study: NCT02807493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal Support Device
Description: Bite plate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group
Study: NCT03993704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHF-535
Description: Oral suspension administered once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LHF-535
Description: Oral suspension administered once daily for 14 days
Study: NCT01848860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesh coverage of the staple line
Description: Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
Study: NCT03673046

Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
Description: 12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered cognitive behavioral therapy (CBT) for body dysmorphic disorder (BDD)
Description: 12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
Study: NCT00717093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Study: NCT02428270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: Small molecule inhibitor of focal adhesion kinase (FAK)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
Study: NCT04340778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal dinoprostone
Description: vaginal dinoprostone 3 mg will be given 3 hours before copper IUD insertion plus inert placebo cream will be applied on the cervix at the time of IUD insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-prilocaine Cream
Description: Lidocaine-prilocaine Cream will be applied on the cervix at the time of IUD insertion plus vaginal placebo tablet will be given 3 hours prior to IUD insertion
Study: NCT00026234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given intra-arterially

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given intra-arterially

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study: NCT02403024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InterWalk
Description: Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list control
Description: Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
Study: NCT00988975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of pelvicol graft
Description: Pelvicol graft
Study: NCT02490254

Intervention type: OTHER
Intervention: Surveillance card
Study: NCT01860820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geko device
Study: NCT00194714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu Peptide Vaccine
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00752284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronectomy
Description: Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Excision
Description: Total excision of lower third molar
Study: NCT00112294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (Taxane)
Description: IV, 225 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (Taxane)
Description: IV, 225 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (Taxane)
Description: IV, 75 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (Taxane)
Description: IV, 75 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6, q 3 weeks (6 cycles maximum)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6, q 3 weeks (6 cycles maximum)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Intravenous, 400 mg/m\^2, initial dose followed by 250 mg/m\^2, weekly starting on Week 2
Study: NCT00654654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (azficel-T)
Description: 1. Collection of 3 mm biopsies~2. Two injection treatments of facial wrinkles and creases~3. Conduct of study assessments
Study: NCT02714231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac sodium (cataflam)
Description: The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butyl bromide (buscopan)
Description: The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
Study: NCT04092920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser and SLA
Description: ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings.
Study: NCT02924376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
Study: NCT03804164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend Emerging from the Haze psychoeducational sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04203160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given intravenously
Study: NCT01482975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored computer based intervention
Description: Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored computer intervention
Description: Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
Study: NCT04210180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5 mg nightly for days 1-3, then 0.5 mg twice daily for days 4-7; then 1 mg twice daily for the remaining 11 weeks.
Study: NCT02540499

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DIBH VMAT
Description: Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
Study: NCT03517254

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
Study: NCT04210180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-cigarette
Description: Each G6 prefilled cartomizer contains a 50/50 blend nicotine salt with 35mg nicotine strength.
Study: NCT03281382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-hIL12
Description: Oncolytic adenovirus expressing two suicide genes and human IL-12
Study: NCT03403413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: muscle vibration during walking
Description: Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group. Gait assessment both with and without muscle vibration were collected at follow-up after 12 sessions of gait training with muscle vibration.
Study: NCT01736891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Tablets, qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, qd
Study: NCT04356820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Data collection took about 10 to 15 minutes. Then the woman invited to the examination room was asked to pull one of the envelopes with the names of the groups. The women who pulled the acupressure envelope were given a semi-sitting position where the acupressure application can feel comfortable and the researcher can easily apply the acupressure points. Before the acupressure application, massage was applied for 30 seconds to ensure circulation. Afterwards, 90 seconds consecutive pressures were applied to the specified acupressure points in a certain order (SP 6, Li 4), taking into account the direction of the meridian. After the examination, the pain formed during the gynecological examination was evaluated by applying the Short Form-McGill Pain Questionnaire without leaving the examination room
Study: NCT03517254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training program
Description: One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
Study: NCT00316953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04367272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First Arthroplasty
Description: First Knee

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second Arthroplasty
Description: Second Knee
Study: NCT02545036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) daycare model
Description: Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
Study: NCT03366870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy for Insomnia
Description: A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: A web-based program will deliver components of sleep education via an Internet platform.
Study: NCT03315585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: steep pulse device
Description: Applying the steep pulse to treat the patients with Prostate cancer
Study: NCT03732469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
Study: NCT01903005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Higher bioavailability BNX sublingual tablets
Description: Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
Study: NCT00490581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management and supportive housing
Description: patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
Study: NCT00557037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxodiol
Description: Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxodiol
Description: Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
Study: NCT03517254

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strength training program
Description: One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin powder to mimic glutamine,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary recommendations
Description: All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary recommendations
Description: All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
Study: NCT01634282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262
Description: Orally administered once daily
Study: NCT02667821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head positions and spinal manipulation
Description: Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
Study: NCT03180801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted FLU-v
Description: Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted FLU-v
Description: Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: adjuvanted placebo
Description: Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adjuvanted placebo
Description: Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Influenza challenge
Description: On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influenza challenge
Description: On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Influenza challenge
Description: On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.